<table id="L624f13a3-2515-4e83-8358-735eb9f45436" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><caption>Table 3. Lesion Complete Response at 3-Month Post-Treatment for Different Lesion Grades</caption>
<colgroup>
<col width="31%"></col>
<col width="18%"></col>
<col width="16%"></col>
<col width="18%"></col>
<col width="16%"></col>
</colgroup>
<thead>
<tr><td></td><td align="center" colspan="2">Australian Study<br/></td><td align="center" colspan="2"> U.S. Study<br/></td></tr>
<tr><td>Lesion Grade</td><td align="center">
												Metvixia-PDT</td><td align="center">Vehicle PDT</td><td align="center">
												 Metvixia-PDT</td><td align="center">Vehicle PDT</td></tr>
</thead>
<tbody>
<tr><td>Lesion Grade 1 (slightly palpable AK: better felt than seen)</td><td align="center">198/209 (95%)</td><td align="center">12/35 (34%)</td><td align="center">172/196 (88%)</td><td align="center">72/162 (44%)</td></tr>
<tr><td>Lesion Grade 2 (visible and palpable AK: easily seen and felt)</td><td align="center">119/151 (79%)</td><td align="center">9/39 (23%)</td><td align="center">49/64 (77%)</td><td align="center">20/80 (25%)</td></tr>
<tr><td>Total</td><td align="center">317/360 (88%)</td><td align="center">21/74 (28%)</td><td align="center">221/260 (85%)</td><td align="center">92/242 (38%)</td></tr>
</tbody>
</table>